[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdEABB6OFOm5PbJJqbQJhOakJ32ylWezUzUJ-w07w0cI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":76,"rows":83},"Universitair Ziekenhuis Brussel",[4],380,false,88,14,61395,13,291,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Infertility",30,{"name":18,"count":19},"Failed Back Surgery Syndrome",8,{"name":21,"count":22},"Pregnancy",7,{"name":24,"count":25},"Brugada Syndrome",6,{"name":27,"count":25},"Pain",{"name":29,"count":25},"Breast Cancer",{"name":31,"count":25},"Infertility, Female",{"name":33,"count":34},"Multiple Sclerosis",5,[36,41,46,51,56,61,66,71],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03967938","Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes","2024-12-31","Olaparib Oral",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06387901","Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.","2025-05-06","Paclitaxel Chemotherapy",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06097975","A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma","2025-06-01","Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03707808","Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab","2025-12-24","intratumoral injection of autologous CD1c (BDCA-1)+ myDC",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07448831","A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a\u002Fb cN0M0 Melanoma.","2026-06-30","Pembrolizumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03233152","A Phase I\u002FII Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","2026-11-17","Ipilimumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03883542","Sub-type Specific Genomic Mutations in sBOTs","2026-12-31","genomic mutations study",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05933239","Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients","2027-04-01","68GaNOTA-Anti-MMR-VHH2",[77,78,79,80,81,82],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[84,138,178,200,222,244,262,286,304,322,344,362,388,409,472,533,569,591,621,645,663,687,705,723,741,759,783,808,836,854,872,898,916,938,964,995,1020,1038,1061,1083,1107,1132,1150,1168,1186,1212,1230,1248,1266,1294,1312,1340,1366,1384,1409,1445,1484,1506,1544,1582,1630,1652,1670,1688,1706,1724,1751,1769,1787,1813,1837,1862,1880,1898,1920,1944,1969,1993,2018,2036,2062,2086,2111,2129,2147,2165,2188,2213,2231,2249,2273,2291,2316,2374,2399,2422,2448,2472,2490,2516,2543,2561,2579,2604,2629,2653,2677,2704,2728,2750,2778,2796,2823,2849],{"intervention":75,"totalTrials":85,"cells":86},3,{"EARLY_PHASE1":87,"PHASE1":90,"PHASE2":92,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":88,"activeCount":89},[],0,{"trials":91,"activeCount":89},[],{"trials":93,"activeCount":131,"soonestReadout":74},[94,102,113],{"nctId":72,"briefTitle":73,"status":95,"phases":96,"primaryCompletion":74,"completion":74,"start":97,"enrollment":98,"conditions":99,"interventions":101},"RECRUITING",[79],"2023-03-30",20,[100],"Non-small Cell Lung Cancer",[75],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":11,"conditions":109,"interventions":112},"NCT04168528","Phase I\u002FIIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET\u002FCT","TERMINATED",[78,79],"2024-12-04","2019-11-05",[110,29,111],"Malignant Solid Tumor","Melanoma (Skin)",[75],{"nctId":114,"briefTitle":115,"status":105,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":130},"NCT04758650","Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis",[79],"2025-01-08","2021-01-26",29,[121,122,123,124,125,126,127,128,129],"Solid Malignancy Located in the Head and Neck","Cancer","Carotid Stenosis","Atherosclerosis of Artery","Hodgkin Lymphoma, Adult","Non Hodgkin Lymphoma","HLH","Cardiac Sarcoidosis","Sarcoidosis",[75],1,{"trials":133,"activeCount":89},[],{"trials":135,"activeCount":89},[],{"trials":137,"activeCount":89},[],{"intervention":65,"totalTrials":139,"cells":140},2,{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":142,"activeCount":89},[],{"trials":144,"activeCount":89},[],{"trials":146,"activeCount":131,"soonestReadout":64},[147,157],{"nctId":62,"briefTitle":63,"status":148,"phases":149,"primaryCompletion":64,"completion":64,"start":150,"enrollment":151,"conditions":152,"interventions":154},"ACTIVE_NOT_RECRUITING",[78,79],"2016-11-17",110,[153],"Glioblastoma",[65,155,156],"Nivolumab","Autologous CD1c(BDCA-1)+ \u002FCD141(BDCA-3)+ myDC",{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT02941744","A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases","COMPLETED",[78,79],"2018-12","2019-01","2016-03",56,[167,168],"Stage IIIC Skin Melanoma","Stage IV Skin Melanoma",[170,171],"nivolumab","ipilimumab",{"trials":173,"activeCount":89},[],{"trials":175,"activeCount":89},[],{"trials":177,"activeCount":89},[],{"intervention":155,"totalTrials":139,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":181,"activeCount":89},[],{"trials":183,"activeCount":89},[],{"trials":185,"activeCount":131,"soonestReadout":64},[186,190],{"nctId":62,"briefTitle":63,"status":148,"phases":187,"primaryCompletion":64,"completion":64,"start":150,"enrollment":151,"conditions":188,"interventions":189},[78,79],[153],[65,155,156],{"nctId":158,"briefTitle":159,"status":160,"phases":191,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":192,"interventions":193},[78,79],[167,168],[170,171],{"trials":195,"activeCount":89},[],{"trials":197,"activeCount":89},[],{"trials":199,"activeCount":89},[],{"intervention":40,"totalTrials":131,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":203,"activeCount":89},[],{"trials":205,"activeCount":89},[],{"trials":207,"activeCount":131,"soonestReadout":39},[208],{"nctId":37,"briefTitle":38,"status":148,"phases":209,"primaryCompletion":39,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},[79],"2025-12-31","2019-02-07",540,[214],"Advanced Cancers Harbouring Mutations in HRG",[40],{"trials":217,"activeCount":89},[],{"trials":219,"activeCount":89},[],{"trials":221,"activeCount":89},[],{"intervention":60,"totalTrials":131,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":225,"activeCount":89},[],{"trials":227,"activeCount":89},[],{"trials":229,"activeCount":131,"soonestReadout":59},[230],{"nctId":57,"briefTitle":58,"status":95,"phases":231,"primaryCompletion":59,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},[79],"2029-12","2025-04-17",49,[236],"Melanoma (Skin Cancer)",[60],{"trials":239,"activeCount":89},[],{"trials":241,"activeCount":89},[],{"trials":243,"activeCount":89},[],{"intervention":156,"totalTrials":131,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":247,"activeCount":89},[],{"trials":249,"activeCount":89},[],{"trials":251,"activeCount":131,"soonestReadout":64},[252],{"nctId":62,"briefTitle":63,"status":148,"phases":253,"primaryCompletion":64,"completion":64,"start":150,"enrollment":151,"conditions":254,"interventions":255},[78,79],[153],[65,155,156],{"trials":257,"activeCount":89},[],{"trials":259,"activeCount":89},[],{"trials":261,"activeCount":89},[],{"intervention":55,"totalTrials":131,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":265,"activeCount":89},[],{"trials":267,"activeCount":89},[],{"trials":269,"activeCount":131,"soonestReadout":54},[270],{"nctId":52,"briefTitle":53,"status":95,"phases":271,"primaryCompletion":54,"completion":54,"start":272,"enrollment":273,"conditions":274,"interventions":277},[78,79],"2018-01-29",18,[275,276],"Solid Tumor","Metastases to Soft Tissue",[55,278,279],"Intratumoral injection of ipilimumab and AS01b","IV nivolumab",{"trials":281,"activeCount":89},[],{"trials":283,"activeCount":89},[],{"trials":285,"activeCount":89},[],{"intervention":278,"totalTrials":131,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":289,"activeCount":89},[],{"trials":291,"activeCount":89},[],{"trials":293,"activeCount":131,"soonestReadout":54},[294],{"nctId":52,"briefTitle":53,"status":95,"phases":295,"primaryCompletion":54,"completion":54,"start":272,"enrollment":273,"conditions":296,"interventions":297},[78,79],[275,276],[55,278,279],{"trials":299,"activeCount":89},[],{"trials":301,"activeCount":89},[],{"trials":303,"activeCount":89},[],{"intervention":279,"totalTrials":131,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":307,"activeCount":89},[],{"trials":309,"activeCount":89},[],{"trials":311,"activeCount":131,"soonestReadout":54},[312],{"nctId":52,"briefTitle":53,"status":95,"phases":313,"primaryCompletion":54,"completion":54,"start":272,"enrollment":273,"conditions":314,"interventions":315},[78,79],[275,276],[55,278,279],{"trials":317,"activeCount":89},[],{"trials":319,"activeCount":89},[],{"trials":321,"activeCount":89},[],{"intervention":50,"totalTrials":131,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":342},{"trials":325,"activeCount":89},[],{"trials":327,"activeCount":131,"soonestReadout":49},[328],{"nctId":47,"briefTitle":48,"status":95,"phases":329,"primaryCompletion":49,"completion":330,"start":331,"enrollment":273,"conditions":332,"interventions":334},[78],"2025-12-01","2024-03-15",[333],"Recurrent Glioblastoma",[50,335],"Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary",{"trials":337,"activeCount":89},[],{"trials":339,"activeCount":89},[],{"trials":341,"activeCount":89},[],{"trials":343,"activeCount":89},[],{"intervention":335,"totalTrials":131,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":347,"activeCount":89},[],{"trials":349,"activeCount":131,"soonestReadout":49},[350],{"nctId":47,"briefTitle":48,"status":95,"phases":351,"primaryCompletion":49,"completion":330,"start":331,"enrollment":273,"conditions":352,"interventions":353},[78],[333],[50,335],{"trials":355,"activeCount":89},[],{"trials":357,"activeCount":89},[],{"trials":359,"activeCount":89},[],{"trials":361,"activeCount":89},[],{"intervention":45,"totalTrials":131,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":365,"activeCount":89},[],{"trials":367,"activeCount":89},[],{"trials":369,"activeCount":89},[],{"trials":371,"activeCount":89},[],{"trials":373,"activeCount":89},[],{"trials":375,"activeCount":131,"soonestReadout":44},[376],{"nctId":42,"briefTitle":43,"status":95,"phases":377,"primaryCompletion":44,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":387},[],"2025-10-31","2024-07-30",40,[29,382,383,384,385,386],"Paclitaxel Adverse Reaction","Chemotherapeutic Toxicity","Chemotherapeutic Agent Toxicity","Body Weight","Physical Inactivity",[45],{"intervention":70,"totalTrials":131,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":398,"NA":400},{"trials":391,"activeCount":89},[],{"trials":393,"activeCount":89},[],{"trials":395,"activeCount":89},[],{"trials":397,"activeCount":89},[],{"trials":399,"activeCount":89},[],{"trials":401,"activeCount":131,"soonestReadout":69},[402],{"nctId":67,"briefTitle":68,"status":148,"phases":403,"primaryCompletion":69,"completion":404,"start":405,"enrollment":98,"conditions":406,"interventions":408},[],"2027-07-30","2017-01",[407],"Ovarian Neoplasm Epithelial",[70],{"intervention":410,"totalTrials":411,"cells":412},"Progesterone",4,{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":430,"PHASE4":432,"NA":470},{"trials":414,"activeCount":89},[],{"trials":416,"activeCount":89},[],{"trials":418,"activeCount":89},[419],{"nctId":420,"briefTitle":421,"status":160,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT01147770","Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes",[78,79],"2010-01","2010-06","2008-09",200,[15],[429],"progesterone",{"trials":431,"activeCount":89},[],{"trials":433,"activeCount":89},[434,446,454],{"nctId":435,"briefTitle":436,"status":160,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":445},"NCT02032797","Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.",[81],"2019-09","2012-11",300,[442,443,444],"Cryopreservation","Embryo Implantation","Progesteron",[410],{"nctId":447,"briefTitle":448,"status":160,"phases":449,"primaryCompletion":450,"completion":450,"start":439,"enrollment":440,"conditions":451,"interventions":453},"NCT01940653","Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone",[81],"2017-12",[452],"Progesterone Supplementation",[410],{"nctId":455,"briefTitle":456,"status":160,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":465},"NCT01888744","Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist",[81],"2013-06","2010-09",120,[462,463,464],"Reproductive Endocrinology","Fertility","Optimal Stimulation Protocol",[466,467,468,469,410],"GnRH agonist","GnRH antagonist","hP-hMG","Human chorionic gonadotropin",{"trials":471,"activeCount":89},[],{"intervention":473,"totalTrials":411,"cells":474},"Corifollitropin alfa",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":493,"PHASE4":520,"NA":531},{"trials":476,"activeCount":89},[],{"trials":478,"activeCount":89},[],{"trials":480,"activeCount":89},[481],{"nctId":482,"briefTitle":483,"status":160,"phases":484,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT01732068","Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol",[79],"2013-05","2012-07",51,[15,489],"Poor Ovarian Response",[491,473,492],"Triptorelin","hpHMG",{"trials":494,"activeCount":89},[495,507],{"nctId":496,"briefTitle":497,"status":160,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":503},"NCT01816321","Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial",[80],"2016-05","2013-03",150,[15,489],[473,504,505,506],"recombinant FSH","Ganirelix","hp HMG",{"nctId":508,"briefTitle":509,"status":160,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT03197077","Optimisation of Follicular Recruitment in IVM Cycles",[80],"2022-12-31","2017-11-01",145,[31,515],"Polycystic Ovary Syndrome",[517,518,519],"Corifollitropin Alfa","Follitropin beta","oral contraceptive pill pretreatment",{"trials":521,"activeCount":89},[522],{"nctId":523,"briefTitle":524,"status":160,"phases":525,"primaryCompletion":500,"completion":500,"start":526,"enrollment":527,"conditions":528,"interventions":529},"NCT01633580","D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists",[81],"2011-12",67,[15],[530],"corifollitropin alfa",{"trials":532,"activeCount":89},[],{"intervention":534,"totalTrials":139,"cells":535},"10000 IU urinary HCG",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":557,"NA":567},{"trials":537,"activeCount":89},[],{"trials":539,"activeCount":89},[],{"trials":541,"activeCount":89},[],{"trials":543,"activeCount":89},[544],{"nctId":545,"briefTitle":546,"status":547,"phases":548,"primaryCompletion":549,"completion":459,"start":550,"enrollment":551,"conditions":552,"interventions":555},"NCT00954265","Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)","UNKNOWN",[80],"2007-12","2005-08",130,[553,21,554],"Embryonic Development","VEGF",[534,556],"250 mcg recombinant HCG",{"trials":558,"activeCount":89},[559],{"nctId":560,"briefTitle":561,"status":160,"phases":562,"primaryCompletion":563,"completion":564,"start":550,"enrollment":551,"conditions":565,"interventions":566},"NCT00953628","Endometrial Advancement After Rec or u-HCG Triggering",[81],"2006-12","2008-12",[15],[534,556],{"trials":568,"activeCount":89},[],{"intervention":556,"totalTrials":139,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":583,"NA":589},{"trials":572,"activeCount":89},[],{"trials":574,"activeCount":89},[],{"trials":576,"activeCount":89},[],{"trials":578,"activeCount":89},[579],{"nctId":545,"briefTitle":546,"status":547,"phases":580,"primaryCompletion":549,"completion":459,"start":550,"enrollment":551,"conditions":581,"interventions":582},[80],[553,21,554],[534,556],{"trials":584,"activeCount":89},[585],{"nctId":560,"briefTitle":561,"status":160,"phases":586,"primaryCompletion":563,"completion":564,"start":550,"enrollment":551,"conditions":587,"interventions":588},[81],[15],[534,556],{"trials":590,"activeCount":89},[],{"intervention":592,"totalTrials":139,"cells":593},"human chorionic gonadotropin",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":619},{"trials":595,"activeCount":89},[],{"trials":597,"activeCount":89},[],{"trials":599,"activeCount":89},[],{"trials":601,"activeCount":89},[],{"trials":603,"activeCount":89},[604,615],{"nctId":605,"briefTitle":606,"status":160,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":613},"NCT00750100","Low Dose hCG in the Late Follicular Phase",[81],"2008-01","2008-11","2007-09",70,[15],[592,614],"recombinant gonadotropins",{"nctId":455,"briefTitle":456,"status":160,"phases":616,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":617,"interventions":618},[81],[462,463,464],[466,467,468,469,410],{"trials":620,"activeCount":89},[],{"intervention":622,"totalTrials":131,"cells":623},"epoprostenol",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":643},{"trials":625,"activeCount":89},[],{"trials":627,"activeCount":89},[],{"trials":629,"activeCount":89},[],{"trials":631,"activeCount":89},[],{"trials":633,"activeCount":89},[634],{"nctId":635,"briefTitle":636,"status":160,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":9,"conditions":640,"interventions":642},"NCT01014156","Epoprostenol in Pulmonary Embolism",[81],"2006-06","2004-01",[641],"Acute Pulmonary Embolism",[622],{"trials":644,"activeCount":89},[],{"intervention":614,"totalTrials":131,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":661},{"trials":648,"activeCount":89},[],{"trials":650,"activeCount":89},[],{"trials":652,"activeCount":89},[],{"trials":654,"activeCount":89},[],{"trials":656,"activeCount":89},[657],{"nctId":605,"briefTitle":606,"status":160,"phases":658,"primaryCompletion":608,"completion":609,"start":610,"enrollment":611,"conditions":659,"interventions":660},[81],[15],[592,614],{"trials":662,"activeCount":89},[],{"intervention":664,"totalTrials":131,"cells":665},"clomiphene citrate",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":685},{"trials":667,"activeCount":89},[],{"trials":669,"activeCount":89},[],{"trials":671,"activeCount":89},[],{"trials":673,"activeCount":89},[],{"trials":675,"activeCount":89},[676],{"nctId":677,"briefTitle":678,"status":160,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":380,"conditions":682,"interventions":683},"NCT00835744","Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles",[81],"2012-03","2008-08",[15],[664,684],"gonadotropins",{"trials":686,"activeCount":89},[],{"intervention":684,"totalTrials":131,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":697,"NA":703},{"trials":690,"activeCount":89},[],{"trials":692,"activeCount":89},[],{"trials":694,"activeCount":89},[],{"trials":696,"activeCount":89},[],{"trials":698,"activeCount":89},[699],{"nctId":677,"briefTitle":678,"status":160,"phases":700,"primaryCompletion":680,"completion":680,"start":681,"enrollment":380,"conditions":701,"interventions":702},[81],[15],[664,684],{"trials":704,"activeCount":89},[],{"intervention":466,"totalTrials":131,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":721},{"trials":708,"activeCount":89},[],{"trials":710,"activeCount":89},[],{"trials":712,"activeCount":89},[],{"trials":714,"activeCount":89},[],{"trials":716,"activeCount":89},[717],{"nctId":455,"briefTitle":456,"status":160,"phases":718,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":719,"interventions":720},[81],[462,463,464],[466,467,468,469,410],{"trials":722,"activeCount":89},[],{"intervention":467,"totalTrials":131,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":733,"NA":739},{"trials":726,"activeCount":89},[],{"trials":728,"activeCount":89},[],{"trials":730,"activeCount":89},[],{"trials":732,"activeCount":89},[],{"trials":734,"activeCount":89},[735],{"nctId":455,"briefTitle":456,"status":160,"phases":736,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":737,"interventions":738},[81],[462,463,464],[466,467,468,469,410],{"trials":740,"activeCount":89},[],{"intervention":468,"totalTrials":131,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":757},{"trials":744,"activeCount":89},[],{"trials":746,"activeCount":89},[],{"trials":748,"activeCount":89},[],{"trials":750,"activeCount":89},[],{"trials":752,"activeCount":89},[753],{"nctId":455,"briefTitle":456,"status":160,"phases":754,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":755,"interventions":756},[81],[462,463,464],[466,467,468,469,410],{"trials":758,"activeCount":89},[],{"intervention":760,"totalTrials":131,"cells":761},"Estradiol valerate",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":781},{"trials":763,"activeCount":89},[],{"trials":765,"activeCount":89},[],{"trials":767,"activeCount":89},[],{"trials":769,"activeCount":89},[],{"trials":771,"activeCount":89},[772],{"nctId":773,"briefTitle":774,"status":160,"phases":775,"primaryCompletion":776,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":780},"NCT01218386","Pretreatment With Estradiol Valerate",[81],"2012-01","2010-05",80,[15],[760],{"trials":782,"activeCount":89},[],{"intervention":784,"totalTrials":131,"cells":785},"fast release oro dispersible tramadol 50 mg",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":806},{"trials":787,"activeCount":89},[],{"trials":789,"activeCount":89},[],{"trials":791,"activeCount":89},[],{"trials":793,"activeCount":89},[],{"trials":795,"activeCount":89},[796],{"nctId":797,"briefTitle":798,"status":547,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":805},"NCT02416141","Fast-release Orodispersible Tramadol as Analgesia in Termination of Pregnancy by Vacuum Aspiration.",[81],"2015-11","2015-12","2015-04",128,[463],[784],{"trials":807,"activeCount":89},[],{"intervention":809,"totalTrials":131,"cells":810},"Diazepam 10 MG",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":834},{"trials":812,"activeCount":89},[],{"trials":814,"activeCount":89},[],{"trials":816,"activeCount":89},[],{"trials":818,"activeCount":89},[],{"trials":820,"activeCount":89},[821],{"nctId":822,"briefTitle":823,"status":547,"phases":824,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":828,"interventions":831},"NCT03293017","Baclofen in Managing Acute Alcohol Withdrawal",[81],"2022-02-01","2016-02-01",90,[829,830],"Alcohol Use Disorder","Alcohol Withdrawal",[809,832,833],"Baclofen 30mg","Baclofen 60mg",{"trials":835,"activeCount":89},[],{"intervention":832,"totalTrials":131,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":852},{"trials":839,"activeCount":89},[],{"trials":841,"activeCount":89},[],{"trials":843,"activeCount":89},[],{"trials":845,"activeCount":89},[],{"trials":847,"activeCount":89},[848],{"nctId":822,"briefTitle":823,"status":547,"phases":849,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":850,"interventions":851},[81],[829,830],[809,832,833],{"trials":853,"activeCount":89},[],{"intervention":833,"totalTrials":131,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":870},{"trials":857,"activeCount":89},[],{"trials":859,"activeCount":89},[],{"trials":861,"activeCount":89},[],{"trials":863,"activeCount":89},[],{"trials":865,"activeCount":89},[866],{"nctId":822,"briefTitle":823,"status":547,"phases":867,"primaryCompletion":825,"completion":825,"start":826,"enrollment":827,"conditions":868,"interventions":869},[81],[829,830],[809,832,833],{"trials":871,"activeCount":89},[],{"intervention":873,"totalTrials":131,"cells":874},"Epidural analgesia Ropivacaine",{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":896},{"trials":876,"activeCount":89},[],{"trials":878,"activeCount":89},[],{"trials":880,"activeCount":89},[],{"trials":882,"activeCount":89},[],{"trials":884,"activeCount":89},[885],{"nctId":886,"briefTitle":887,"status":160,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":380,"conditions":892,"interventions":894},"NCT02523755","Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia",[81],"2016-11","2016-12","2015-09",[21,893],"Atelectasis",[873,895],"Absence of epidural analgesia",{"trials":897,"activeCount":89},[],{"intervention":895,"totalTrials":131,"cells":899},{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":906,"PHASE4":908,"NA":914},{"trials":901,"activeCount":89},[],{"trials":903,"activeCount":89},[],{"trials":905,"activeCount":89},[],{"trials":907,"activeCount":89},[],{"trials":909,"activeCount":89},[910],{"nctId":886,"briefTitle":887,"status":160,"phases":911,"primaryCompletion":889,"completion":890,"start":891,"enrollment":380,"conditions":912,"interventions":913},[81],[21,893],[873,895],{"trials":915,"activeCount":89},[],{"intervention":917,"totalTrials":131,"cells":918},"ovarian stimulation",{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":936},{"trials":920,"activeCount":89},[],{"trials":922,"activeCount":89},[],{"trials":924,"activeCount":89},[],{"trials":926,"activeCount":89},[],{"trials":928,"activeCount":89},[929],{"nctId":930,"briefTitle":931,"status":160,"phases":932,"primaryCompletion":777,"completion":777,"start":933,"enrollment":611,"conditions":934,"interventions":935},"NCT01093443","Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days",[81],"2009-11",[15],[917,917],{"trials":937,"activeCount":89},[],{"intervention":939,"totalTrials":131,"cells":940},"N-acetylcysteine",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":962},{"trials":942,"activeCount":89},[],{"trials":944,"activeCount":89},[],{"trials":946,"activeCount":89},[],{"trials":948,"activeCount":89},[],{"trials":950,"activeCount":89},[951],{"nctId":952,"briefTitle":953,"status":547,"phases":954,"primaryCompletion":825,"completion":955,"start":956,"enrollment":957,"conditions":958,"interventions":961},"NCT03221231","N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms",[81],"2023-02-01","2016-05-15",75,[959,960],"Cannabis Use Disorder","Cannabis Dependence",[939],{"trials":963,"activeCount":89},[],{"intervention":965,"totalTrials":131,"cells":966},"Midazolam oral solution",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":993},{"trials":968,"activeCount":89},[],{"trials":970,"activeCount":89},[],{"trials":972,"activeCount":89},[],{"trials":974,"activeCount":89},[],{"trials":976,"activeCount":89},[977],{"nctId":978,"briefTitle":979,"status":547,"phases":980,"primaryCompletion":981,"completion":982,"start":983,"enrollment":501,"conditions":984,"interventions":992},"NCT04273035","Handheld-multimedia Versus Oral Midazolam in Pediatric on Perioperative Anxiety",[81],"2021-12-31","2022-02-28","2020-02-01",[985,986,987,988,989,990,991],"Perioperative Anxiety","Preanesthetic Medication","Inhalation Anesthesia","Ambulatory Surgery","Tonsillectomy","Circumcision","Dental Care",[965],{"trials":994,"activeCount":89},[],{"intervention":996,"totalTrials":131,"cells":997},"300IU rec-LH",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1018},{"trials":999,"activeCount":89},[],{"trials":1001,"activeCount":89},[],{"trials":1003,"activeCount":89},[],{"trials":1005,"activeCount":89},[],{"trials":1007,"activeCount":89},[1008],{"nctId":1009,"briefTitle":1010,"status":547,"phases":1011,"primaryCompletion":608,"completion":1012,"start":1013,"enrollment":380,"conditions":1014,"interventions":1016},"NCT00954811","Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)",[81],"2010-12","2005-09",[21,1015],"Pregnancy Loss",[996,1017],"progesterone 600mg",{"trials":1019,"activeCount":89},[],{"intervention":1017,"totalTrials":131,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1036},{"trials":1023,"activeCount":89},[],{"trials":1025,"activeCount":89},[],{"trials":1027,"activeCount":89},[],{"trials":1029,"activeCount":89},[],{"trials":1031,"activeCount":89},[1032],{"nctId":1009,"briefTitle":1010,"status":547,"phases":1033,"primaryCompletion":608,"completion":1012,"start":1013,"enrollment":380,"conditions":1034,"interventions":1035},[81],[21,1015],[996,1017],{"trials":1037,"activeCount":89},[],{"intervention":1039,"totalTrials":131,"cells":1040},"human menopausal gonadotropin",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1059},{"trials":1042,"activeCount":89},[],{"trials":1044,"activeCount":89},[],{"trials":1046,"activeCount":89},[],{"trials":1048,"activeCount":89},[],{"trials":1050,"activeCount":89},[1051],{"nctId":1052,"briefTitle":1053,"status":160,"phases":1054,"primaryCompletion":933,"completion":1055,"start":1056,"enrollment":16,"conditions":1057,"interventions":1058},"NCT00976651","Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium",[81],"2009-12","2009-01",[15],[1039],{"trials":1060,"activeCount":89},[],{"intervention":1062,"totalTrials":131,"cells":1063},"Fast-release Orodispersible Tramadol",{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1081},{"trials":1065,"activeCount":89},[],{"trials":1067,"activeCount":89},[],{"trials":1069,"activeCount":89},[],{"trials":1071,"activeCount":89},[],{"trials":1073,"activeCount":89},[1074],{"nctId":1075,"briefTitle":1076,"status":160,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":609,"enrollment":803,"conditions":1079,"interventions":1080},"NCT00893412","Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography",[81],"2009-04",[15,27],[1062],{"trials":1082,"activeCount":89},[],{"intervention":1084,"totalTrials":131,"cells":1085},"Lipiodol",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1103,"NA":1105},{"trials":1087,"activeCount":89},[],{"trials":1089,"activeCount":89},[],{"trials":1091,"activeCount":89},[],{"trials":1093,"activeCount":89},[1094],{"nctId":1095,"briefTitle":1096,"status":547,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":98,"conditions":1100,"interventions":1102},"NCT03542331","Endometrial Effects of Lipiodol",[80],"2020-01","2018-03-01",[1101],"Female Infertility",[1084],{"trials":1104,"activeCount":89},[],{"trials":1106,"activeCount":89},[],{"intervention":1108,"totalTrials":131,"cells":1109},"Lanthanum Carbonate",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1128,"NA":1130},{"trials":1111,"activeCount":89},[],{"trials":1113,"activeCount":89},[],{"trials":1115,"activeCount":89},[],{"trials":1117,"activeCount":89},[1118],{"nctId":1119,"briefTitle":1120,"status":547,"phases":1121,"primaryCompletion":511,"completion":511,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1127},"NCT03346369","Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis",[80],"2017-08-18",35,[1125,1126],"Secondary Hyperoxaluria","Nephrolithiasis",[1108],{"trials":1129,"activeCount":89},[],{"trials":1131,"activeCount":89},[],{"intervention":504,"totalTrials":131,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1146,"NA":1148},{"trials":1135,"activeCount":89},[],{"trials":1137,"activeCount":89},[],{"trials":1139,"activeCount":89},[],{"trials":1141,"activeCount":89},[1142],{"nctId":496,"briefTitle":497,"status":160,"phases":1143,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":1144,"interventions":1145},[80],[15,489],[473,504,505,506],{"trials":1147,"activeCount":89},[],{"trials":1149,"activeCount":89},[],{"intervention":505,"totalTrials":131,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1164,"NA":1166},{"trials":1153,"activeCount":89},[],{"trials":1155,"activeCount":89},[],{"trials":1157,"activeCount":89},[],{"trials":1159,"activeCount":89},[1160],{"nctId":496,"briefTitle":497,"status":160,"phases":1161,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":1162,"interventions":1163},[80],[15,489],[473,504,505,506],{"trials":1165,"activeCount":89},[],{"trials":1167,"activeCount":89},[],{"intervention":506,"totalTrials":131,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1182,"NA":1184},{"trials":1171,"activeCount":89},[],{"trials":1173,"activeCount":89},[],{"trials":1175,"activeCount":89},[],{"trials":1177,"activeCount":89},[1178],{"nctId":496,"briefTitle":497,"status":160,"phases":1179,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":1180,"interventions":1181},[80],[15,489],[473,504,505,506],{"trials":1183,"activeCount":89},[],{"trials":1185,"activeCount":89},[],{"intervention":1187,"totalTrials":131,"cells":1188},"Late follicular phase stimulation with recombinant-human FSH",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1208,"NA":1210},{"trials":1190,"activeCount":89},[],{"trials":1192,"activeCount":89},[],{"trials":1194,"activeCount":89},[],{"trials":1196,"activeCount":89},[1197],{"nctId":1198,"briefTitle":1199,"status":160,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT03767218","Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase",[80],"2022-05-27","2022-11-25","2018-11-01",71,[31],[1187,1207],"Early follicular phase stimulation with recombinant-human FSH",{"trials":1209,"activeCount":89},[],{"trials":1211,"activeCount":89},[],{"intervention":1207,"totalTrials":131,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":89},[],{"trials":1217,"activeCount":89},[],{"trials":1219,"activeCount":89},[],{"trials":1221,"activeCount":89},[1222],{"nctId":1198,"briefTitle":1199,"status":160,"phases":1223,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1224,"interventions":1225},[80],[31],[1187,1207],{"trials":1227,"activeCount":89},[],{"trials":1229,"activeCount":89},[],{"intervention":518,"totalTrials":131,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1244,"NA":1246},{"trials":1233,"activeCount":89},[],{"trials":1235,"activeCount":89},[],{"trials":1237,"activeCount":89},[],{"trials":1239,"activeCount":89},[1240],{"nctId":508,"briefTitle":509,"status":160,"phases":1241,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":1242,"interventions":1243},[80],[31,515],[517,518,519],{"trials":1245,"activeCount":89},[],{"trials":1247,"activeCount":89},[],{"intervention":519,"totalTrials":131,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1262,"NA":1264},{"trials":1251,"activeCount":89},[],{"trials":1253,"activeCount":89},[],{"trials":1255,"activeCount":89},[],{"trials":1257,"activeCount":89},[1258],{"nctId":508,"briefTitle":509,"status":160,"phases":1259,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":1260,"interventions":1261},[80],[31,515],[517,518,519],{"trials":1263,"activeCount":89},[],{"trials":1265,"activeCount":89},[],{"intervention":1267,"totalTrials":131,"cells":1268},"Taurolidine Urokinase",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1290,"NA":1292},{"trials":1270,"activeCount":89},[],{"trials":1272,"activeCount":89},[],{"trials":1274,"activeCount":89},[],{"trials":1276,"activeCount":89},[1277],{"nctId":1278,"briefTitle":1279,"status":160,"phases":1280,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":1284,"conditions":1285,"interventions":1288},"NCT02036255","Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase",[80],"2017-07","2018-05","2015-05",68,[1286,1287],"Patency","Infection",[1267,1289],"Taurolidine Heparin",{"trials":1291,"activeCount":89},[],{"trials":1293,"activeCount":89},[],{"intervention":1289,"totalTrials":131,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":89},[],{"trials":1299,"activeCount":89},[],{"trials":1301,"activeCount":89},[],{"trials":1303,"activeCount":89},[1304],{"nctId":1278,"briefTitle":1279,"status":160,"phases":1305,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":1284,"conditions":1306,"interventions":1307},[80],[1286,1287],[1267,1289],{"trials":1309,"activeCount":89},[],{"trials":1311,"activeCount":89},[],{"intervention":1313,"totalTrials":131,"cells":1314},"Valproic Acid",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1336,"NA":1338},{"trials":1316,"activeCount":89},[],{"trials":1318,"activeCount":89},[],{"trials":1320,"activeCount":89},[],{"trials":1322,"activeCount":89},[1323],{"nctId":1324,"briefTitle":1325,"status":547,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1335},"NCT02896270","Valproic Acid for Idiopathic Nephrotic Syndrome",[79,80],"2019-10","2019-12","2016-10",15,[1332,1333,1334],"Idiopathic Nephrotic Syndrome","Focal Segmental Glomerulosclerosis","Minimal Change Disease",[1313],{"trials":1337,"activeCount":89},[],{"trials":1339,"activeCount":89},[],{"intervention":1341,"totalTrials":131,"cells":1342},"Myo-inositol",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1362,"NA":1364},{"trials":1344,"activeCount":89},[],{"trials":1346,"activeCount":89},[],{"trials":1348,"activeCount":89},[],{"trials":1350,"activeCount":89},[1351],{"nctId":1352,"briefTitle":1353,"status":547,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1357,"conditions":1358,"interventions":1360},"NCT03767569","Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients",[80],"2020-04","2018-09-01",134,[1359,1101],"PCOS",[1341,1361],"Folic Acid",{"trials":1363,"activeCount":89},[],{"trials":1365,"activeCount":89},[],{"intervention":1361,"totalTrials":131,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":89},[],{"trials":1371,"activeCount":89},[],{"trials":1373,"activeCount":89},[],{"trials":1375,"activeCount":89},[1376],{"nctId":1352,"briefTitle":1353,"status":547,"phases":1377,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1357,"conditions":1378,"interventions":1379},[80],[1359,1101],[1341,1361],{"trials":1381,"activeCount":89},[],{"trials":1383,"activeCount":89},[],{"intervention":1385,"totalTrials":131,"cells":1386},"Erector spinae plane block with ropivacaine 3.75mg\u002Fml",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1405,"NA":1407},{"trials":1388,"activeCount":89},[],{"trials":1390,"activeCount":89},[],{"trials":1392,"activeCount":89},[],{"trials":1394,"activeCount":89},[1395],{"nctId":1396,"briefTitle":1397,"status":547,"phases":1398,"primaryCompletion":1399,"completion":955,"start":1400,"enrollment":460,"conditions":1401,"interventions":1404},"NCT04400721","Efficacy of an Erector Spinae Plane Block in VATS\u002FRATS",[80],"2022-06-28","2020-07-01",[1402,1403],"Pain, Postoperative","Post-Op Complication",[1385],{"trials":1406,"activeCount":89},[],{"trials":1408,"activeCount":89},[],{"intervention":491,"totalTrials":85,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1412,"activeCount":89},[],{"trials":1414,"activeCount":89},[],{"trials":1416,"activeCount":89},[1417,1427,1431],{"nctId":1418,"briefTitle":1419,"status":547,"phases":1420,"primaryCompletion":1421,"completion":210,"start":1422,"enrollment":16,"conditions":1423,"interventions":1425},"NCT04616729","DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation",[78,79],"2025-11-30","2022-11-01",[1424],"Breast Cancer Female",[1426,491],"Triptorelin 3.75 MG",{"nctId":482,"briefTitle":483,"status":160,"phases":1428,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":1429,"interventions":1430},[79],[15,489],[491,473,492],{"nctId":1432,"briefTitle":1433,"status":160,"phases":1434,"primaryCompletion":485,"completion":485,"start":486,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT01732094","Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders",[79],57,[15,489],[491,1438,492],"Corifollitropin alfa 150μg",{"trials":1440,"activeCount":89},[],{"trials":1442,"activeCount":89},[],{"trials":1444,"activeCount":89},[],{"intervention":1446,"totalTrials":139,"cells":1447},"Trametinib",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1478,"PHASE4":1480,"NA":1482},{"trials":1449,"activeCount":89},[],{"trials":1451,"activeCount":89},[],{"trials":1453,"activeCount":89},[1454,1466],{"nctId":1455,"briefTitle":1456,"status":160,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1464},"NCT04059224","TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma",[79],"2023-06-30","2019-01-28",45,[1462,1463],"Stage IV Melanoma","Stage III Melanoma",[1446,1465],"Dabrafenib",{"nctId":1467,"briefTitle":1468,"status":547,"phases":1469,"primaryCompletion":1470,"completion":1471,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1476},"NCT03754179","Dabrafenib\u002FTrametinib\u002FHydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma",[78,79],"2021-12-01","2022-07-01","2018-01-23",63,[1475],"Melanoma",[1465,1446,1477],"Hydroxychloroquine",{"trials":1479,"activeCount":89},[],{"trials":1481,"activeCount":89},[],{"trials":1483,"activeCount":89},[],{"intervention":1465,"totalTrials":139,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1487,"activeCount":89},[],{"trials":1489,"activeCount":89},[],{"trials":1491,"activeCount":89},[1492,1496],{"nctId":1455,"briefTitle":1456,"status":160,"phases":1493,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":1460,"conditions":1494,"interventions":1495},[79],[1462,1463],[1446,1465],{"nctId":1467,"briefTitle":1468,"status":547,"phases":1497,"primaryCompletion":1470,"completion":1471,"start":1472,"enrollment":1473,"conditions":1498,"interventions":1499},[78,79],[1475],[1465,1446,1477],{"trials":1501,"activeCount":89},[],{"trials":1503,"activeCount":89},[],{"trials":1505,"activeCount":89},[],{"intervention":1507,"totalTrials":139,"cells":1508},"Paclitaxel",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1510,"activeCount":89},[],{"trials":1512,"activeCount":89},[],{"trials":1514,"activeCount":89},[1515,1527],{"nctId":1516,"briefTitle":1517,"status":547,"phases":1518,"primaryCompletion":1519,"completion":1520,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1525},"NCT03810872","An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation",[79],"2020-12","2022-12","2017-06-21",87,[1524],"Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation",[1526,1507],"Afatinib",{"nctId":1528,"briefTitle":1529,"status":160,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1283,"enrollment":1473,"conditions":1533,"interventions":1534},"NCT04224922","Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer",[79],"2016-07","2017-05",[29],[1507,1535,1536,1537],"Carboplatinum","Epirubicin","Cyclophosphamide",{"trials":1539,"activeCount":89},[],{"trials":1541,"activeCount":89},[],{"trials":1543,"activeCount":89},[],{"intervention":1545,"totalTrials":139,"cells":1546},"Avelumab",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1548,"activeCount":89},[],{"trials":1550,"activeCount":89},[],{"trials":1552,"activeCount":89},[1553,1564],{"nctId":1554,"briefTitle":1555,"status":160,"phases":1556,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":1560,"interventions":1562},"NCT03291314","Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma",[79],"2019-01-01","2017-05-03",52,[1561],"Recurrent Glioblastoma (WHO-Grade IV Glioma)",[1563,1545],"Axitinib",{"nctId":1565,"briefTitle":1566,"status":547,"phases":1567,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":1571,"interventions":1573},"NCT04571632","Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab\u002FIpilimumab+ Dendritic Cells in Solid Tumors",[79],"2023-12","2020-09-22",36,[1572,275],"Non Small Cell Lung Cancer",[1545,1574,1575],"Ipilimumab 5 MG\u002FML","Pembrolizumab 100 MG in 4 ML",{"trials":1577,"activeCount":89},[],{"trials":1579,"activeCount":89},[],{"trials":1581,"activeCount":89},[],{"intervention":1583,"totalTrials":139,"cells":1584},"68GaNOTA-Anti-HER2 VHH1",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1586,"activeCount":89},[],{"trials":1588,"activeCount":89},[],{"trials":1590,"activeCount":89},[1591,1614],{"nctId":1592,"briefTitle":1593,"status":547,"phases":1594,"primaryCompletion":1595,"completion":1596,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1613},"NCT03924466","Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET\u002FCT in Breast Carcinoma Patients",[79],"2024-11","2024-12","2019-04-01",55,[1600,1601,1602,1603,1604,1605,1606,1607,1572,1608,1609,1610,1611,1612],"Metastatic Breast Carcinoma","Locally Advanced Breast Cancer","Cancer of Pancreas","Solid Tumor With Intermediate or High HER2 Expression","Salivary Gland Cancer","Gastric Cancer","Endometrial Cancer","Uterine Cancer","Biliary Tract Cancer","Cholangiocarcinoma","Colorectal Cancer","Urothelial Carcinoma","Prostate Cancer",[1583],{"nctId":1615,"briefTitle":1616,"status":105,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":22,"conditions":1620,"interventions":1623},"NCT03331601","Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients",[79],"2025-10-14","2017-10-16",[1621,1622],"Carcinoma","Receptor, ErbB-2",[1583],{"trials":1625,"activeCount":89},[],{"trials":1627,"activeCount":89},[],{"trials":1629,"activeCount":89},[],{"intervention":492,"totalTrials":139,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1633,"activeCount":89},[],{"trials":1635,"activeCount":89},[],{"trials":1637,"activeCount":89},[1638,1642],{"nctId":482,"briefTitle":483,"status":160,"phases":1639,"primaryCompletion":485,"completion":485,"start":486,"enrollment":487,"conditions":1640,"interventions":1641},[79],[15,489],[491,473,492],{"nctId":1432,"briefTitle":1433,"status":160,"phases":1643,"primaryCompletion":485,"completion":485,"start":486,"enrollment":1435,"conditions":1644,"interventions":1645},[79],[15,489],[491,1438,492],{"trials":1647,"activeCount":89},[],{"trials":1649,"activeCount":89},[],{"trials":1651,"activeCount":89},[],{"intervention":1526,"totalTrials":131,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":89},[],{"trials":1657,"activeCount":89},[],{"trials":1659,"activeCount":89},[1660],{"nctId":1516,"briefTitle":1517,"status":547,"phases":1661,"primaryCompletion":1519,"completion":1520,"start":1521,"enrollment":1522,"conditions":1662,"interventions":1663},[79],[1524],[1526,1507],{"trials":1665,"activeCount":89},[],{"trials":1667,"activeCount":89},[],{"trials":1669,"activeCount":89},[],{"intervention":1535,"totalTrials":131,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1673,"activeCount":89},[],{"trials":1675,"activeCount":89},[],{"trials":1677,"activeCount":89},[1678],{"nctId":1528,"briefTitle":1529,"status":160,"phases":1679,"primaryCompletion":1531,"completion":1532,"start":1283,"enrollment":1473,"conditions":1680,"interventions":1681},[79],[29],[1507,1535,1536,1537],{"trials":1683,"activeCount":89},[],{"trials":1685,"activeCount":89},[],{"trials":1687,"activeCount":89},[],{"intervention":1536,"totalTrials":131,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":89},[],{"trials":1693,"activeCount":89},[],{"trials":1695,"activeCount":89},[1696],{"nctId":1528,"briefTitle":1529,"status":160,"phases":1697,"primaryCompletion":1531,"completion":1532,"start":1283,"enrollment":1473,"conditions":1698,"interventions":1699},[79],[29],[1507,1535,1536,1537],{"trials":1701,"activeCount":89},[],{"trials":1703,"activeCount":89},[],{"trials":1705,"activeCount":89},[],{"intervention":1537,"totalTrials":131,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":89},[],{"trials":1711,"activeCount":89},[],{"trials":1713,"activeCount":89},[1714],{"nctId":1528,"briefTitle":1529,"status":160,"phases":1715,"primaryCompletion":1531,"completion":1532,"start":1283,"enrollment":1473,"conditions":1716,"interventions":1717},[79],[29],[1507,1535,1536,1537],{"trials":1719,"activeCount":89},[],{"trials":1721,"activeCount":89},[],{"trials":1723,"activeCount":89},[],{"intervention":1725,"totalTrials":131,"cells":1726},"Regorafenib 40 MG Oral",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1728,"activeCount":89},[],{"trials":1730,"activeCount":89},[],{"trials":1732,"activeCount":89},[1733],{"nctId":1734,"briefTitle":1735,"status":547,"phases":1736,"primaryCompletion":1596,"completion":1737,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1743},"NCT05370807","A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma",[79],"2025-03","2022-10-03",48,[1741,1742],"Melanoma Stage III","Melanoma Stage IV",[1725,1744],"Triplet therapy",{"trials":1746,"activeCount":89},[],{"trials":1748,"activeCount":89},[],{"trials":1750,"activeCount":89},[],{"intervention":1744,"totalTrials":131,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1754,"activeCount":89},[],{"trials":1756,"activeCount":89},[],{"trials":1758,"activeCount":89},[1759],{"nctId":1734,"briefTitle":1735,"status":547,"phases":1760,"primaryCompletion":1596,"completion":1737,"start":1738,"enrollment":1739,"conditions":1761,"interventions":1762},[79],[1741,1742],[1725,1744],{"trials":1764,"activeCount":89},[],{"trials":1766,"activeCount":89},[],{"trials":1768,"activeCount":89},[],{"intervention":1426,"totalTrials":131,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1772,"activeCount":89},[],{"trials":1774,"activeCount":89},[],{"trials":1776,"activeCount":89},[1777],{"nctId":1418,"briefTitle":1419,"status":547,"phases":1778,"primaryCompletion":1421,"completion":210,"start":1422,"enrollment":16,"conditions":1779,"interventions":1780},[78,79],[1424],[1426,491],{"trials":1782,"activeCount":89},[],{"trials":1784,"activeCount":89},[],{"trials":1786,"activeCount":89},[],{"intervention":1788,"totalTrials":131,"cells":1789},"Actrapid HM",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1791,"activeCount":89},[],{"trials":1793,"activeCount":89},[],{"trials":1795,"activeCount":89},[1796],{"nctId":1797,"briefTitle":1798,"status":160,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1806},"NCT00654121","Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives",[79],"2004-04","2007-11","2000-02",112,[1805],"Diabetes, Type I",[1788],{"trials":1808,"activeCount":89},[],{"trials":1810,"activeCount":89},[],{"trials":1812,"activeCount":89},[],{"intervention":1814,"totalTrials":131,"cells":1815},"Dabrafenib + Trametinib",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1817,"activeCount":89},[],{"trials":1819,"activeCount":89},[],{"trials":1821,"activeCount":89},[1822],{"nctId":1823,"briefTitle":1824,"status":160,"phases":1825,"primaryCompletion":450,"completion":450,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT02296996","Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients",[79],"2014-10",25,[1829],"Malignant Melanoma",[1814],{"trials":1832,"activeCount":89},[],{"trials":1834,"activeCount":89},[],{"trials":1836,"activeCount":89},[],{"intervention":1838,"totalTrials":131,"cells":1839},"Levosimendan 2.5 milligram\u002Fmilliliter Injectable Solutiondose Inhaled",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1841,"activeCount":89},[],{"trials":1843,"activeCount":89},[],{"trials":1845,"activeCount":89},[1846],{"nctId":1847,"briefTitle":1848,"status":547,"phases":1849,"primaryCompletion":1595,"completion":1850,"start":1851,"enrollment":25,"conditions":1852,"interventions":1854},"NCT06387862","Pharmacokinetics of Inhaled Levosimendan",[79],"2025-01","2024-02-01",[1853],"Left Ventricular Dysfunction",[1838,1855],"Levosimendan 2.5 milligram\u002Fmilliliter Injectable Solutiondose Intravenous",{"trials":1857,"activeCount":89},[],{"trials":1859,"activeCount":89},[],{"trials":1861,"activeCount":89},[],{"intervention":1855,"totalTrials":131,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1865,"activeCount":89},[],{"trials":1867,"activeCount":89},[],{"trials":1869,"activeCount":89},[1870],{"nctId":1847,"briefTitle":1848,"status":547,"phases":1871,"primaryCompletion":1595,"completion":1850,"start":1851,"enrollment":25,"conditions":1872,"interventions":1873},[79],[1853],[1838,1855],{"trials":1875,"activeCount":89},[],{"trials":1877,"activeCount":89},[],{"trials":1879,"activeCount":89},[],{"intervention":1563,"totalTrials":131,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1883,"activeCount":89},[],{"trials":1885,"activeCount":89},[],{"trials":1887,"activeCount":89},[1888],{"nctId":1554,"briefTitle":1555,"status":160,"phases":1889,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":1890,"interventions":1891},[79],[1561],[1563,1545],{"trials":1893,"activeCount":89},[],{"trials":1895,"activeCount":89},[],{"trials":1897,"activeCount":89},[],{"intervention":1899,"totalTrials":131,"cells":1900},"sorafenib + erlotinib",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1914,"PHASE4":1916,"NA":1918},{"trials":1902,"activeCount":89},[],{"trials":1904,"activeCount":89},[],{"trials":1906,"activeCount":89},[1907],{"nctId":1908,"briefTitle":1909,"status":547,"phases":1910,"primaryCompletion":609,"completion":1078,"start":1801,"enrollment":1739,"conditions":1911,"interventions":1913},"NCT00722969","Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",[79],[1912],"Non-Small Cell Lung Cancer",[1899],{"trials":1915,"activeCount":89},[],{"trials":1917,"activeCount":89},[],{"trials":1919,"activeCount":89},[],{"intervention":1921,"totalTrials":131,"cells":1922},"Erlotinib",{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1924,"activeCount":89},[],{"trials":1926,"activeCount":89},[],{"trials":1928,"activeCount":89},[1929],{"nctId":1930,"briefTitle":1931,"status":547,"phases":1932,"start":1933,"enrollment":380,"conditions":1934,"interventions":1937},"NCT00339586","First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene",[79],"2006-01",[1935,1912,1936],"Lung Neoplasms","Adenocarcinoma, Bronchiolo-Alveolar",[1921],{"trials":1939,"activeCount":89},[],{"trials":1941,"activeCount":89},[],{"trials":1943,"activeCount":89},[],{"intervention":1945,"totalTrials":131,"cells":1946},"Dendritic cell therapy",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1948,"activeCount":89},[],{"trials":1950,"activeCount":89},[],{"trials":1952,"activeCount":89},[1953],{"nctId":1954,"briefTitle":1955,"status":160,"phases":1956,"primaryCompletion":891,"completion":1957,"start":1958,"enrollment":8,"conditions":1959,"interventions":1962},"NCT01676779","mRNA Electroporated Autologous Dendritic Cells for Stage III\u002FIV Melanoma",[79],"2016-09","2012-10",[1960,1961],"Malignant Melanoma Stage III","Malignant Melanoma Stage IV",[1945],{"trials":1964,"activeCount":89},[],{"trials":1966,"activeCount":89},[],{"trials":1968,"activeCount":89},[],{"intervention":1970,"totalTrials":131,"cells":1971},"ChAgly CD3",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1973,"activeCount":89},[],{"trials":1975,"activeCount":89},[],{"trials":1977,"activeCount":89},[1978],{"nctId":1979,"briefTitle":1980,"status":160,"phases":1981,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":778,"conditions":1984,"interventions":1986},"NCT00627146","Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients",[79],"2007-03","2000-06",[1985],"Diabetes Mellitus, Type 1",[1970],{"trials":1988,"activeCount":89},[],{"trials":1990,"activeCount":89},[],{"trials":1992,"activeCount":89},[],{"intervention":1994,"totalTrials":131,"cells":1995},"Cisplatinum",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":1997,"activeCount":89},[],{"trials":1999,"activeCount":89},[],{"trials":2001,"activeCount":89},[2002],{"nctId":2003,"briefTitle":2004,"status":547,"phases":2005,"completion":2006,"start":2007,"enrollment":16,"conditions":2008,"interventions":2010},"NCT00379717","Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)",[78,79],"2008-04","2006-11",[2009],"Non-Small-Cell Lung Carcinoma",[1994,2011],"Docetaxel",{"trials":2013,"activeCount":89},[],{"trials":2015,"activeCount":89},[],{"trials":2017,"activeCount":89},[],{"intervention":2011,"totalTrials":131,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2021,"activeCount":89},[],{"trials":2023,"activeCount":89},[],{"trials":2025,"activeCount":89},[2026],{"nctId":2003,"briefTitle":2004,"status":547,"phases":2027,"completion":2006,"start":2007,"enrollment":16,"conditions":2028,"interventions":2029},[78,79],[2009],[1994,2011],{"trials":2031,"activeCount":89},[],{"trials":2033,"activeCount":89},[],{"trials":2035,"activeCount":89},[],{"intervention":2037,"totalTrials":131,"cells":2038},"Lanreotide",{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2040,"activeCount":89},[],{"trials":2042,"activeCount":89},[],{"trials":2044,"activeCount":89},[2045],{"nctId":2046,"briefTitle":2047,"status":547,"phases":2048,"primaryCompletion":801,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2055},"NCT02054637","Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy",[79],"2016-04","2014-04",10,[2053,2054],"Acid Reflux Esophagitis","Non-acid Reflux Esophagitis",[2037],{"trials":2057,"activeCount":89},[],{"trials":2059,"activeCount":89},[],{"trials":2061,"activeCount":89},[],{"intervention":2063,"totalTrials":131,"cells":2064},"glucose 20%",{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2066,"activeCount":89},[],{"trials":2068,"activeCount":89},[],{"trials":2070,"activeCount":89},[2071],{"nctId":2072,"briefTitle":2073,"status":547,"phases":2074,"primaryCompletion":1826,"completion":2075,"start":2076,"enrollment":426,"conditions":2077,"interventions":2079},"NCT00800085","Beta Cell Function in (Pre) Type 1 Diabetes",[78,79],"2015-10","2006-10",[2078],"Type 1 Diabetes",[2063],{"trials":2081,"activeCount":89},[],{"trials":2083,"activeCount":89},[],{"trials":2085,"activeCount":89},[],{"intervention":2087,"totalTrials":131,"cells":2088},"Pyridostigmine",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2090,"activeCount":89},[],{"trials":2092,"activeCount":89},[],{"trials":2094,"activeCount":89},[2095],{"nctId":2096,"briefTitle":2097,"status":2098,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":89,"conditions":2102,"interventions":2104},"NCT06915181","Clinical Usefulness and Influence on Esophageal Motility of Pyridostigmine for Dysphagia in Systemic Sclerosis","WITHDRAWN",[79],"2024-05-01","2023-12-01",[2103],"Systemic Sclerosis With Dysphagia",[2087],{"trials":2106,"activeCount":89},[],{"trials":2108,"activeCount":89},[],{"trials":2110,"activeCount":89},[],{"intervention":1477,"totalTrials":131,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2114,"activeCount":89},[],{"trials":2116,"activeCount":89},[],{"trials":2118,"activeCount":89},[2119],{"nctId":1467,"briefTitle":1468,"status":547,"phases":2120,"primaryCompletion":1470,"completion":1471,"start":1472,"enrollment":1473,"conditions":2121,"interventions":2122},[78,79],[1475],[1465,1446,1477],{"trials":2124,"activeCount":89},[],{"trials":2126,"activeCount":89},[],{"trials":2128,"activeCount":89},[],{"intervention":1574,"totalTrials":131,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":89},[],{"trials":2134,"activeCount":89},[],{"trials":2136,"activeCount":89},[2137],{"nctId":1565,"briefTitle":1566,"status":547,"phases":2138,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":2139,"interventions":2140},[79],[1572,275],[1545,1574,1575],{"trials":2142,"activeCount":89},[],{"trials":2144,"activeCount":89},[],{"trials":2146,"activeCount":89},[],{"intervention":1575,"totalTrials":131,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":89},[],{"trials":2152,"activeCount":89},[],{"trials":2154,"activeCount":89},[2155],{"nctId":1565,"briefTitle":1566,"status":547,"phases":2156,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":2157,"interventions":2158},[79],[1572,275],[1545,1574,1575],{"trials":2160,"activeCount":89},[],{"trials":2162,"activeCount":89},[],{"trials":2164,"activeCount":89},[],{"intervention":2166,"totalTrials":131,"cells":2167},"Sulfamethoxazole",{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2169,"activeCount":89},[],{"trials":2171,"activeCount":89},[],{"trials":2173,"activeCount":89},[2174],{"nctId":2175,"briefTitle":2176,"status":547,"phases":2177,"primaryCompletion":1329,"completion":1329,"start":2075,"enrollment":1330,"conditions":2178,"interventions":2181},"NCT02640443","Sulfamethoxazole for the Treatment of Primary PREPL Deficiency",[79],[2179,2180],"Hypotonia Cystinuria Syndrome","Isolated PREPL Deficiency",[2166],{"trials":2183,"activeCount":89},[],{"trials":2185,"activeCount":89},[],{"trials":2187,"activeCount":89},[],{"intervention":2189,"totalTrials":131,"cells":2190},"ATG-MMF-TAC",{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2192,"activeCount":89},[],{"trials":2194,"activeCount":89},[],{"trials":2196,"activeCount":89},[2197],{"nctId":2198,"briefTitle":2199,"status":547,"phases":2200,"primaryCompletion":2201,"completion":2201,"start":2076,"enrollment":2202,"conditions":2203,"interventions":2204},"NCT00798785","Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients",[78,79],"2014-12",50,[1985],[2189,2205,2206],"ATG-Rituximab-MMF-TAC","ATG-basilixumab-MMF-TAC",{"trials":2208,"activeCount":89},[],{"trials":2210,"activeCount":89},[],{"trials":2212,"activeCount":89},[],{"intervention":2205,"totalTrials":131,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":89},[],{"trials":2218,"activeCount":89},[],{"trials":2220,"activeCount":89},[2221],{"nctId":2198,"briefTitle":2199,"status":547,"phases":2222,"primaryCompletion":2201,"completion":2201,"start":2076,"enrollment":2202,"conditions":2223,"interventions":2224},[78,79],[1985],[2189,2205,2206],{"trials":2226,"activeCount":89},[],{"trials":2228,"activeCount":89},[],{"trials":2230,"activeCount":89},[],{"intervention":2206,"totalTrials":131,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":89},[],{"trials":2236,"activeCount":89},[],{"trials":2238,"activeCount":89},[2239],{"nctId":2198,"briefTitle":2199,"status":547,"phases":2240,"primaryCompletion":2201,"completion":2201,"start":2076,"enrollment":2202,"conditions":2241,"interventions":2242},[78,79],[1985],[2189,2205,2206],{"trials":2244,"activeCount":89},[],{"trials":2246,"activeCount":89},[],{"trials":2248,"activeCount":89},[],{"intervention":2250,"totalTrials":131,"cells":2251},"Decitabine",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2253,"activeCount":89},[],{"trials":2255,"activeCount":89},[],{"trials":2257,"activeCount":89},[2258],{"nctId":2259,"briefTitle":2260,"status":160,"phases":2261,"primaryCompletion":890,"completion":1281,"start":2262,"enrollment":2263,"conditions":2264,"interventions":2266},"NCT02316028","Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)",[78,79],"2014-03",11,[2265,1610],"Liver Metastasis",[2250],{"trials":2268,"activeCount":89},[],{"trials":2270,"activeCount":89},[],{"trials":2272,"activeCount":89},[],{"intervention":1438,"totalTrials":131,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2285,"PHASE4":2287,"NA":2289},{"trials":2276,"activeCount":89},[],{"trials":2278,"activeCount":89},[],{"trials":2280,"activeCount":89},[2281],{"nctId":1432,"briefTitle":1433,"status":160,"phases":2282,"primaryCompletion":485,"completion":485,"start":486,"enrollment":1435,"conditions":2283,"interventions":2284},[79],[15,489],[491,1438,492],{"trials":2286,"activeCount":89},[],{"trials":2288,"activeCount":89},[],{"trials":2290,"activeCount":89},[],{"intervention":2292,"totalTrials":131,"cells":2293},"Trimix",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2314},{"trials":2295,"activeCount":89},[],{"trials":2297,"activeCount":89},[2298],{"nctId":2299,"briefTitle":2300,"status":547,"phases":2301,"primaryCompletion":2302,"completion":2303,"start":2304,"enrollment":1570,"conditions":2305,"interventions":2307},"NCT03788083","Intratumoral TriMix Injections in Early Breast Cancer Patients",[78],"2024-09-30","2024-12-30","2018-11-12",[1424,2306],"Early-stage Breast Cancer",[2292],{"trials":2309,"activeCount":89},[],{"trials":2311,"activeCount":89},[],{"trials":2313,"activeCount":89},[],{"trials":2315,"activeCount":89},[],{"intervention":2317,"totalTrials":34,"cells":2318},"HCG",{"EARLY_PHASE1":2319,"PHASE1":2330,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2357},{"trials":2320,"activeCount":89},[2321],{"nctId":2322,"briefTitle":2323,"status":160,"phases":2324,"primaryCompletion":2325,"completion":2326,"start":1078,"enrollment":440,"conditions":2327,"interventions":2329},"NCT01414673","HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles",[77],"2011-07","2011-08",[2328],"Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI",[2317],{"trials":2331,"activeCount":89},[],{"trials":2333,"activeCount":89},[],{"trials":2335,"activeCount":89},[],{"trials":2337,"activeCount":89},[2338,2348],{"nctId":2339,"briefTitle":2340,"status":547,"phases":2341,"primaryCompletion":2342,"completion":2343,"start":776,"enrollment":1330,"conditions":2344,"interventions":2347},"NCT01768247","HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)",[81],"2013-12","2014-01",[2345,2346],"Endometrial Thickness","Pregnancy Outcome",[2317],{"nctId":2349,"briefTitle":2350,"status":160,"phases":2351,"primaryCompletion":438,"completion":438,"start":2343,"enrollment":2352,"conditions":2353,"interventions":2355},"NCT02145819","Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?",[81],240,[2354],"Supervision of Pregnancy Resulting From In-vitro Fertilization",[2356],"hCG",{"trials":2358,"activeCount":89},[2359,2366],{"nctId":2360,"briefTitle":2361,"status":160,"phases":2362,"primaryCompletion":2363,"completion":1056,"start":2076,"enrollment":501,"conditions":2364,"interventions":2365},"NCT00809107","Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration",[82],"2008-07",[15],[2317],{"nctId":2367,"briefTitle":2368,"status":160,"phases":2369,"primaryCompletion":2370,"completion":500,"start":2371,"enrollment":460,"conditions":2372,"interventions":2373},"NCT01892826","Frozen Blastocyst Transfer in Natural Cycle",[82],"2012-02","2009-02",[15],[2356],{"intervention":2375,"totalTrials":131,"cells":2376},"Gaviscon Syrup",{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2383,"PHASE4":2385,"NA":2387},{"trials":2378,"activeCount":89},[],{"trials":2380,"activeCount":89},[],{"trials":2382,"activeCount":89},[],{"trials":2384,"activeCount":89},[],{"trials":2386,"activeCount":89},[],{"trials":2388,"activeCount":89},[2389],{"nctId":2390,"briefTitle":2391,"status":160,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":2202,"conditions":2396,"interventions":2398},"NCT02783378","48 Hours Esophagal pH-monitoring With and Without Gaviscon",[82],"2017-08-01","2017-12-31","2016-02-24",[2397],"Gastroesophageal Reflux",[2375],{"intervention":2400,"totalTrials":131,"cells":2401},"Glucose",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2403,"activeCount":89},[],{"trials":2405,"activeCount":89},[],{"trials":2407,"activeCount":89},[],{"trials":2409,"activeCount":89},[],{"trials":2411,"activeCount":89},[],{"trials":2413,"activeCount":89},[2414],{"nctId":2415,"briefTitle":2416,"status":547,"phases":2417,"primaryCompletion":2418,"completion":1531,"start":2325,"enrollment":2419,"conditions":2420,"interventions":2421},"NCT01402037","Beta Cell Function in (Pre)Type 1 Diabetes",[82],"2015-07",100,[2078],[2400],{"intervention":2423,"totalTrials":131,"cells":2424},"Alprazolam 0.5 mg",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2426,"activeCount":89},[],{"trials":2428,"activeCount":89},[],{"trials":2430,"activeCount":89},[],{"trials":2432,"activeCount":89},[],{"trials":2434,"activeCount":89},[],{"trials":2436,"activeCount":89},[2437],{"nctId":2438,"briefTitle":2439,"status":547,"phases":2440,"primaryCompletion":2441,"completion":2442,"start":1557,"enrollment":2443,"conditions":2444,"interventions":2447},"NCT03576456","Sedative Premedication in Coronary Angiography",[82],"2020-01-01","2020-08-01",264,[2445,2446],"Coronary Angiography","Sedative Premedication",[2423],{"intervention":2449,"totalTrials":131,"cells":2450},"rhCG= Ovitrelle®, 250g\u002F0.5ml = 26000IU\u002Fml, Merck-Serono",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2457,"PHASE4":2459,"NA":2461},{"trials":2452,"activeCount":89},[],{"trials":2454,"activeCount":89},[],{"trials":2456,"activeCount":89},[],{"trials":2458,"activeCount":89},[],{"trials":2460,"activeCount":89},[],{"trials":2462,"activeCount":89},[2463],{"nctId":2464,"briefTitle":2465,"status":547,"phases":2466,"primaryCompletion":1458,"completion":1458,"start":2467,"enrollment":1123,"conditions":2468,"interventions":2470},"NCT05370794","Is in Vitro Maturation of Oocytes Influenced by the Origin of Gonadotropins Used in Maturation Medium: is There a Difference in Efficiency When Using Urinary Versus Recombinant Produced Follicle Stimulating Hormone and Human Chorionic Gonadotropin",[],"2022-04-19",[2469],"In Vitro Maturation of Oocytes",[2449,2471],"rFSH = Gonal F®, 300IU\u002F0.5ml, Merck-Serono",{"intervention":2471,"totalTrials":131,"cells":2473},{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2480,"PHASE4":2482,"NA":2484},{"trials":2475,"activeCount":89},[],{"trials":2477,"activeCount":89},[],{"trials":2479,"activeCount":89},[],{"trials":2481,"activeCount":89},[],{"trials":2483,"activeCount":89},[],{"trials":2485,"activeCount":89},[2486],{"nctId":2464,"briefTitle":2465,"status":547,"phases":2487,"primaryCompletion":1458,"completion":1458,"start":2467,"enrollment":1123,"conditions":2488,"interventions":2489},[],[2469],[2449,2471],{"intervention":2491,"totalTrials":131,"cells":2492},"Ropivacaine",{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2494,"activeCount":89},[],{"trials":2496,"activeCount":89},[],{"trials":2498,"activeCount":89},[],{"trials":2500,"activeCount":89},[],{"trials":2502,"activeCount":89},[],{"trials":2504,"activeCount":89},[2505],{"nctId":2506,"briefTitle":2507,"status":105,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":2511,"enrollment":2512,"conditions":2513,"interventions":2515},"NCT04868058","Serratus Anterior or Erector Spinae Block for Hybrid Arrhythmia Ablation Surgery",[82],"2021-05-11","2024-12-01","2020-10-02",28,[2514],"Arrhythmia",[2491],{"intervention":2517,"totalTrials":131,"cells":2518},"Pregnyl®",{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2520,"activeCount":89},[],{"trials":2522,"activeCount":89},[],{"trials":2524,"activeCount":89},[],{"trials":2526,"activeCount":89},[],{"trials":2528,"activeCount":89},[],{"trials":2530,"activeCount":89},[2531],{"nctId":2532,"briefTitle":2533,"status":160,"phases":2534,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2540},"NCT02148393","Implantation Enhancement by Elective Cryopreservation of All Viable Embryos",[82],"2017-02-28","2014-05",212,[15,2539],"OHSS",[2517,2541,2542],"Utrogestan®","Progynova®",{"intervention":2541,"totalTrials":131,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2546,"activeCount":89},[],{"trials":2548,"activeCount":89},[],{"trials":2550,"activeCount":89},[],{"trials":2552,"activeCount":89},[],{"trials":2554,"activeCount":89},[],{"trials":2556,"activeCount":89},[2557],{"nctId":2532,"briefTitle":2533,"status":160,"phases":2558,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":2537,"conditions":2559,"interventions":2560},[82],[15,2539],[2517,2541,2542],{"intervention":2542,"totalTrials":131,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2564,"activeCount":89},[],{"trials":2566,"activeCount":89},[],{"trials":2568,"activeCount":89},[],{"trials":2570,"activeCount":89},[],{"trials":2572,"activeCount":89},[],{"trials":2574,"activeCount":89},[2575],{"nctId":2532,"briefTitle":2533,"status":160,"phases":2576,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":2537,"conditions":2577,"interventions":2578},[82],[15,2539],[2517,2541,2542],{"intervention":2580,"totalTrials":131,"cells":2581},"Sevoflurane",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2583,"activeCount":89},[],{"trials":2585,"activeCount":89},[],{"trials":2587,"activeCount":89},[],{"trials":2589,"activeCount":89},[],{"trials":2591,"activeCount":89},[],{"trials":2593,"activeCount":89},[2594],{"nctId":2595,"briefTitle":2596,"status":160,"phases":2597,"primaryCompletion":2598,"completion":2598,"start":2599,"enrollment":2600,"conditions":2601,"interventions":2603},"NCT04939753","Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis",[],"2023-04-01","2021-05-26",1000,[2602],"Nephrogenic Diabetes Insipidus",[2580],{"intervention":2605,"totalTrials":131,"cells":2606},"Ulipristal Acetate 5 MG Oral",{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2608,"activeCount":89},[],{"trials":2610,"activeCount":89},[],{"trials":2612,"activeCount":89},[],{"trials":2614,"activeCount":89},[],{"trials":2616,"activeCount":89},[],{"trials":2618,"activeCount":89},[2619],{"nctId":2620,"briefTitle":2621,"status":547,"phases":2622,"primaryCompletion":210,"completion":2623,"start":2624,"enrollment":380,"conditions":2625,"interventions":2628},"NCT04028986","Esmya Versus Surgery Before IVF\u002FICSI",[],"2026-06-01","2016-01-01",[2626,31,2627],"Fibroid; Uterus Tumor, Complicating Pregnancy","Surgical Procedure, Unspecified",[2605],{"intervention":2630,"totalTrials":131,"cells":2631},"Dexmedetomidine",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2640,"NA":2642},{"trials":2633,"activeCount":89},[],{"trials":2635,"activeCount":89},[],{"trials":2637,"activeCount":89},[],{"trials":2639,"activeCount":89},[],{"trials":2641,"activeCount":89},[],{"trials":2643,"activeCount":89},[2644],{"nctId":2645,"briefTitle":2646,"status":160,"phases":2647,"primaryCompletion":2418,"completion":2418,"start":2648,"enrollment":2649,"conditions":2650,"interventions":2652},"NCT02555605","Dexmedetomidine Sedation in Children With Respiratory Morbidities",[],"2013-11",19,[2651],"Respiratory Morbidity",[2630],{"intervention":2654,"totalTrials":131,"cells":2655},"Ajmaline test",{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2660,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2657,"activeCount":89},[],{"trials":2659,"activeCount":89},[],{"trials":2661,"activeCount":89},[],{"trials":2663,"activeCount":89},[],{"trials":2665,"activeCount":89},[],{"trials":2667,"activeCount":89},[2668],{"nctId":2669,"briefTitle":2670,"status":547,"phases":2671,"primaryCompletion":2672,"completion":2673,"start":2674,"enrollment":2419,"conditions":2675,"interventions":2676},"NCT03491475","Echocardiography During Ajmaline Test",[],"2019-03-31","2019-05-31","2018-03-26",[24],[2654],{"intervention":2678,"totalTrials":131,"cells":2679},"Propofol",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2686,"PHASE4":2688,"NA":2690},{"trials":2681,"activeCount":89},[],{"trials":2683,"activeCount":89},[],{"trials":2685,"activeCount":89},[],{"trials":2687,"activeCount":89},[],{"trials":2689,"activeCount":89},[],{"trials":2691,"activeCount":89},[2692],{"nctId":2693,"briefTitle":2694,"status":160,"phases":2695,"primaryCompletion":2696,"completion":2696,"start":2697,"enrollment":2698,"conditions":2699,"interventions":2703},"NCT04839666","Hypersensitivity Reactions to Propofol in Children",[],"2016-08-31","2010-01-01",2299,[2700,2701,2702],"Hypersensitivity","Allergy, Egg","Soy Allergy",[2678],{"intervention":2705,"totalTrials":131,"cells":2706},"blood test",{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2708,"activeCount":89},[],{"trials":2710,"activeCount":89},[],{"trials":2712,"activeCount":89},[],{"trials":2714,"activeCount":89},[],{"trials":2716,"activeCount":89},[],{"trials":2718,"activeCount":89},[2719],{"nctId":2720,"briefTitle":2721,"status":160,"phases":2722,"primaryCompletion":2101,"completion":2101,"start":2723,"enrollment":2724,"conditions":2725,"interventions":2727},"NCT05511272","The Circadian Variability of Serum Progesterone During the Day of a Frozen Embryo Transfer",[82],"2022-08-15",44,[2726],"Fertility Disorders",[2705],{"intervention":2729,"totalTrials":131,"cells":2730},"micronized progesterone",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2732,"activeCount":89},[],{"trials":2734,"activeCount":89},[],{"trials":2736,"activeCount":89},[],{"trials":2738,"activeCount":89},[],{"trials":2740,"activeCount":89},[],{"trials":2742,"activeCount":89},[2743],{"nctId":2744,"briefTitle":2745,"status":160,"phases":2746,"primaryCompletion":2747,"completion":486,"start":425,"enrollment":440,"conditions":2748,"interventions":2749},"NCT01046708","Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate",[82],"2009-08",[15],[2729],{"intervention":2751,"totalTrials":131,"cells":2752},"NaCl predilution",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2754,"activeCount":89},[],{"trials":2756,"activeCount":89},[],{"trials":2758,"activeCount":89},[],{"trials":2760,"activeCount":89},[],{"trials":2762,"activeCount":89},[],{"trials":2764,"activeCount":89},[2765],{"nctId":2766,"briefTitle":2767,"status":160,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":2051,"conditions":2771,"interventions":2776},"NCT03314363","Plasma CO2 Removal Due to CRRT and Its Influence on Indirect Calorimetry",[82],"2019-03-15","2017-04-26",[2772,2773,2774,2775],"Continuous Renal Replacement Therapy","CO2 Removal","Nutrition Poor","Acute Renal Failure",[2751,2777],"double ultrafiltration",{"intervention":2777,"totalTrials":131,"cells":2779},{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2781,"activeCount":89},[],{"trials":2783,"activeCount":89},[],{"trials":2785,"activeCount":89},[],{"trials":2787,"activeCount":89},[],{"trials":2789,"activeCount":89},[],{"trials":2791,"activeCount":89},[2792],{"nctId":2766,"briefTitle":2767,"status":160,"phases":2793,"primaryCompletion":2769,"completion":2769,"start":2770,"enrollment":2051,"conditions":2794,"interventions":2795},[82],[2772,2773,2774,2775],[2751,2777],{"intervention":2797,"totalTrials":131,"cells":2798},"Structured multi-disciplinary approach",{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2800,"activeCount":89},[],{"trials":2802,"activeCount":89},[],{"trials":2804,"activeCount":89},[],{"trials":2806,"activeCount":89},[],{"trials":2808,"activeCount":89},[],{"trials":2810,"activeCount":89},[2811],{"nctId":2812,"briefTitle":2813,"status":547,"phases":2814,"primaryCompletion":2302,"completion":2302,"start":2815,"enrollment":2816,"conditions":2817,"interventions":2822},"NCT06161350","The Multi-disciplinary Approach of Children With Feeding Difficulties and Tube Feeding in UZB Between 2000 and 2021",[],"2023-11-08",330,[2818,2819,2820,2821],"Oral Aversion","Enteral Nutrition","Parenteral Nutrition","Tube Feeding",[2797],{"intervention":2824,"totalTrials":131,"cells":2825},"Ajmaline",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2832,"PHASE4":2834,"NA":2836},{"trials":2827,"activeCount":89},[],{"trials":2829,"activeCount":89},[],{"trials":2831,"activeCount":89},[],{"trials":2833,"activeCount":89},[],{"trials":2835,"activeCount":89},[],{"trials":2837,"activeCount":89},[2838],{"nctId":2839,"briefTitle":2840,"status":547,"phases":2841,"primaryCompletion":2842,"completion":2842,"start":2843,"enrollment":1827,"conditions":2844,"interventions":2848},"NCT04580992","Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial",[],"2022-10-31","2020-11-16",[24,2845,2846,2847],"Channelopathies","Ventricular Fibrillation","Cardiac Death",[2824],{"intervention":2850,"totalTrials":131,"cells":2851},"ATG-Sirolimus-Tacrolimus",{"EARLY_PHASE1":2852,"PHASE1":2854,"PHASE2":2856,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2853,"activeCount":89},[],{"trials":2855,"activeCount":89},[],{"trials":2857,"activeCount":89},[],{"trials":2859,"activeCount":89},[],{"trials":2861,"activeCount":89},[],{"trials":2863,"activeCount":89},[2864],{"nctId":2865,"briefTitle":2866,"status":105,"phases":2867,"conditions":2868,"interventions":2870},"NCT00409461","Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts",[82],[2869,2078],"Islet Transplantation",[2850]]